Literature DB >> 31467405

Dendritic cells in cancer immunology and immunotherapy.

Stefanie K Wculek1, Francisco J Cueto1, Adriana M Mujal2,3, Ignacio Melero4,5,6,7, Matthew F Krummel2, David Sancho8.   

Abstract

Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.

Entities:  

Mesh:

Year:  2019        PMID: 31467405     DOI: 10.1038/s41577-019-0210-z

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  417 in total

Review 1.  Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.

Authors:  Edward F Fritsch; Ute E Burkhardt; Nir Hacohen; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2020-12       Impact factor: 11.151

Review 2.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

Review 3.  The Immune-Modulatory Properties of iPSC-Derived Antigen-Presenting Cells.

Authors:  Mania Ackermann; Anna Christina Dragon; Nico Lachmann
Journal:  Transfus Med Hemother       Date:  2020-11-16       Impact factor: 3.747

Review 4.  Natural and Induced Tolerogenic Dendritic Cells.

Authors:  Courtney A Iberg; Daniel Hawiger
Journal:  J Immunol       Date:  2020-02-15       Impact factor: 5.422

5.  A dendritic cell multitasks to tackle cancer.

Authors:  Marianne Burbage; Sebastian Amigorena
Journal:  Nature       Date:  2020-08       Impact factor: 49.962

Review 6.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 7.  Long noncoding RNA loss in immune suppression in cancer.

Authors:  Qingsong Hu; Sergey D Egranov; Chunru Lin; Liuqing Yang
Journal:  Pharmacol Ther       Date:  2020-05-29       Impact factor: 12.310

8.  CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells.

Authors:  Luke Riggan; Andrew D Hildreth; Marion Rolot; Yung-Yu Wong; William Satyadi; Ryan Sun; Christopher Huerta; Timothy E O'Sullivan
Journal:  Cell Rep       Date:  2020-05-19       Impact factor: 9.423

Review 9.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

Review 10.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.